Vimarsana
Biggest News Aggregation in the World

Aperam Sa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aperam Sa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aperam Sa Today - Breaking & Trending Today

Analysts' Downgrades for August 2nd (APEMY, BBVA, BGFV, BUSE, CEQP, CMBM, DRVN, EA, EXAS, GNMLF) - Vimarsana News

Analysts' Downgrades for August 2nd (APEMY, BBVA, BGFV, BUSE, CEQP, CMBM, DRVN, EA, EXAS, GNMLF)

Analysts’ downgrades for Wednesday, August 2nd: Aperam (OTCMKTS:APEMY) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating. Banco Bilbao Vizcaya Argentaria (NYSE:BBVA) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating. Big 5 Sporting Goods (NASDAQ:BGFV) was downgraded by analysts at Lake […]

Investment Analysts' Upgrades for May 31st (AMDUF, APEMY, CGHLY, CLX, CPE, CRNLF, CTT, CVNA, DBSDY, DEO) - Vimarsana News

Investment Analysts' Upgrades for May 31st (AMDUF, APEMY, CGHLY, CLX, CPE, CRNLF, CTT, CVNA, DBSDY, DEO)

Investment Analysts’ upgrades for Tuesday, May 31st: Amundi (OTCMKTS:AMDUF) was upgraded by analysts at Keefe, Bruyette & Woods from a market perform rating to an outperform rating. Aperam (OTCMKTS:APEMY) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating. China Gas (OTCMKTS:CGHLY) was upgraded by analysts at Daiwa Capital […]

Investment Analysts' Downgrades for May 9th (ADXN, AGIL, AJX, AKUS, ALHC, ALPMY, ALVR, APEMY, ATRA, MTW) - Vimarsana News

Investment Analysts' Downgrades for May 9th (ADXN, AGIL, AJX, AKUS, ALHC, ALPMY, ALVR, APEMY, ATRA, MTW)

Investment Analysts’ downgrades for Monday, May 9th: Addex Therapeutics (NASDAQ:ADXN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company’s lead […]